| 000 | 01706 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517225854.0 | ||
| 264 | 0 | _c20191211 | |
| 008 | 201912s 0 0 eng d | ||
| 022 | _a1499-2752 | ||
| 024 | 7 |
_a10.3899/jrheum.170953 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlharbi, Samar | |
| 245 | 0 | 0 |
_aEpidemiology and Survival of Systemic Sclerosis-Systemic Lupus Erythematosus Overlap Syndrome. _h[electronic resource] |
| 260 |
_bThe Journal of rheumatology _c10 2018 |
||
| 300 |
_a1406-1410 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge Factors |
| 650 | 0 | 4 |
_aAntibodies, Anticardiolipin _xblood |
| 650 | 0 | 4 |
_aCanada _xepidemiology |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypertension, Pulmonary _xetiology |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aLongitudinal Studies |
| 650 | 0 | 4 |
_aLupus Coagulation Inhibitor _xblood |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _xepidemiology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aProportional Hazards Models |
| 650 | 0 | 4 |
_aScleroderma, Systemic _xepidemiology |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aUndifferentiated Connective Tissue Diseases _xcomplications |
| 700 | 1 | _aAhmad, Zareen | |
| 700 | 1 | _aBookman, Arthur A | |
| 700 | 1 | _aTouma, Zahi | |
| 700 | 1 | _aSanchez-Guerrero, Jorge | |
| 700 | 1 | _aMitsakakis, Nicholas | |
| 700 | 1 | _aJohnson, Sindhu R | |
| 773 | 0 |
_tThe Journal of rheumatology _gvol. 45 _gno. 10 _gp. 1406-1410 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3899/jrheum.170953 _zAvailable from publisher's website |
| 999 |
_c28632710 _d28632710 |
||